These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36978160)

  • 61. Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia.
    Rodriguez-Jimenez R; Bagney A; Mezquita L; Martinez-Gras I; Sanchez-Morla EM; Mesa N; Ibañez MI; Diez-Martin J; Jimenez-Arriero MA; Lobo A; Santos JL; Palomo T;
    Schizophr Res; 2013 Jan; 143(1):77-83. PubMed ID: 23201306
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The reliability and validity of general psychotic rating scales with people with mild and moderate intellectual disabilities: an empirical investigation.
    Hatton C; Haddock G; Taylor JL; Coldwell J; Crossley R; Peckham N
    J Intellect Disabil Res; 2005 Jul; 49(Pt 7):490-500. PubMed ID: 15966956
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model.
    Anderson AE; Reise SP; Marder SR; Mansolf M; Han C; Bilder RM
    Innov Clin Neurosci; 2017 Dec; 14(11-12):41-53. PubMed ID: 29410936
    [No Abstract]   [Full Text] [Related]  

  • 64. Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia.
    Apiquian R; Elena Ulloa R; Herrera-Estrella M; Moreno-Gómez A; Erosa S; Contreras V; Nicolini H
    Schizophr Res; 2009 Jul; 112(1-3):181-6. PubMed ID: 19398302
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI).
    Kølbæk P; Blicher AB; Buus CW; Feller SG; Holm T; Dines D; O'Leary KM; Sørensen RS; Opler M; Correll CU; Mors O; Bech P; Østergaard SD
    Nord J Psychiatry; 2018 Aug; 72(6):431-436. PubMed ID: 30037286
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.
    Kring AM; Gur RE; Blanchard JJ; Horan WP; Reise SP
    Am J Psychiatry; 2013 Feb; 170(2):165-72. PubMed ID: 23377637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessing positive and negative symptoms in children and adolescents.
    Fields JH; Grochowski S; Lindenmayer JP; Kay SR; Grosz D; Hyman RB; Alexander G
    Am J Psychiatry; 1994 Feb; 151(2):249-53. PubMed ID: 8296898
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.
    Dollfus S; Mach C; Morello R
    Schizophr Bull; 2016 May; 42(3):571-8. PubMed ID: 26564898
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
    Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Huff W; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Möller HJ; Riedel M
    Schizophr Res; 2009 Sep; 113(2-3):210-7. PubMed ID: 19560901
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.
    Emsley RA; Oosthuizen PP; Joubert AF; Roberts MC; Stein DJ
    J Clin Psychiatry; 1999 Nov; 60(11):747-51. PubMed ID: 10584762
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Psychometric evaluation of medication adherence rating scale (MARS) among Nigerian patients with schizophrenia.
    Sowunmi OA; Onifade PO
    Niger J Clin Pract; 2019 Sep; 22(9):1281-1285. PubMed ID: 31489867
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale.
    Boyer L; Richieri R; Guedj E; Faget-Agius C; Loundou A; Llorca PM; Auquier P; Lançon C
    Compr Psychiatry; 2013 Oct; 54(7):1016-22. PubMed ID: 23731897
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phenomenology of first-episode psychosis in schizophrenia, bipolar disorder, and unipolar depression: a comparative analysis.
    Rosen C; Marvin R; Reilly JL; Deleon O; Harris MS; Keedy SK; Solari H; Weiden P; Sweeney JA
    Clin Schizophr Relat Psychoses; 2012 Oct; 6(3):145-51. PubMed ID: 23006239
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Self-Evaluation of Negative Symptoms in Differentiating Deficit Schizophrenia: The Comparison of Sensitivity and Specificity with Other Tools.
    Samochowiec J; Jabłoński M; Plichta P; Piotrowski P; Stańczykiewicz B; Bielawski T; Misiak B
    Psychopathology; 2023; 56(6):453-461. PubMed ID: 36878191
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Time-stability of the "Functional Remission of General Schizophrenia" (FROGS) scale.
    Lançon C; Baylé FJ; Llorca PM; Rouillon F; Caci H; Lancrenon S; Gorwood P
    Eur Psychiatry; 2012 Aug; 27(6):437-41. PubMed ID: 21571505
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Deriu L; Lepori T; Maccioni R; Milia P; Sarritzu E; Tusconi M; Carpiniello B;
    Psychiatry Res; 2013 Dec; 210(3):739-44. PubMed ID: 24007858
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS).
    Forbes C; Blanchard JJ; Bennett M; Horan WP; Kring A; Gur R
    Schizophr Res; 2010 Dec; 124(1-3):36-42. PubMed ID: 20869848
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia.
    Rekhi G; Alphs L; Ang MS; Lee J
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1433-1441. PubMed ID: 31761524
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.